Technology news and discussion on TalkFuse.
Isomorphic Labs secures $5bn to advance AI-designed drugs towards trials
Developed over time first seen 21 hours ago
Isomorphic Labs has raised $5 billion in a Series C funding round to advance its AI-designed drug candidates towards clinical trials. The financing strengthens the company’s effort to turn computational drug design into potential medicines, though its reported results remain at the preclinical stage.
Greenoaks and Sequoia Capital co-led the round, joined by Andreessen Horowitz and existing investors. Spun out of Google DeepMind in 2021, Isomorphic builds on AlphaFold and plans to develop its drug-design engine and expand into more types of medicine; it has reported positive preclinical results in oncology and immunology. The funding follows a $2.1 billion Series B in May, and the company did not disclose its valuation.
- Sources
- 2
- Outlets
- 2
- Left · Centre · Right
- 0 · 0 · 1
In short
- Isomorphic Labs raised $5 billion to advance AI-designed drugs towards trials.
- Its reported oncology and immunology results are preclinical.
- The company plans to develop its platform and explore more types of medicine.
How this story developed
- 17 hours ago The latest account specifies that Andreessen Horowitz was a new investor and names Alphabet’s GV and CapitalG among the existing backers, while noting that the candidates have shown preclinical results rather than clinical outcomes.
- 17 hours ago Isomorphic Labs raised $5 billion in a Series C round to move its AI-designed drug candidates towards clinical trials, backed by Greenoaks, Sequoia Capital, Andreessen Horowitz and existing investors.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The funding could help Isomorphic turn promising computational work into treatments by improving its design engine and moving candidates towards clinical trials. Supporters may see the investment as a way to accelerate research in areas such as cancer and immunology, while backing a platform with potential to make drug discovery more effective.
The case against
The scale of the raise may be premature when the reported results are still preclinical and have not yet shown that the candidates are safe or effective in people. Sceptics may argue that AI-designed drugs still face the usual scientific and clinical hurdles, and that substantial investment in one platform risks outpacing the evidence for its benefits.
Explained simply
Isomorphic Labs is a biotechnology company spun out of Google DeepMind in 2021. It uses artificial intelligence to help design potential medicines, drawing on work such as AlphaFold, a system developed by DeepMind to predict the shapes of proteins.
Drug candidates must pass laboratory and animal studies before they can be tested in people in clinical trials. Isomorphic has reported promising preclinical results in cancer and immune-system research, but these are not evidence that its candidates are safe or effective in patients.
The company is backed by investors including Greenoaks and Sequoia Capital, alongside Andreessen Horowitz and existing supporters. Its work matters because it tests whether AI can help researchers develop medicines more efficiently, while clinical trials will be needed to establish whether the approach produces treatments.
Coverage · 2 sources
AI Entertainment Health Medicine Research Science Technology TV
Read the full article at the source →
Originally published by TechCrunch as “Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials”.